Payer Coverage Decisions vs FDA Labelling in Wet AMD

Payer Challenges in the Management of Wet AMDПодробнее

Lipid Management: Coverage Criteria vs FDA LabelingПодробнее

Wet AMD: Understanding the Role of Anti-VEGF TherapyПодробнее

Access and Cost-Benefit Analyses for Wet AMD TreatmentsПодробнее

Addressing Underrecognition of Wet AMDПодробнее

Patient Cost Considerations in Wet AMD ManagementПодробнее

Deciding Among Anti-VEGF Therapies in Wet AMDПодробнее

Payer Criteria for Anti-VEGF Therapies in Wet AMDПодробнее

Payer Policy and Provider Choice in Wet AMDПодробнее

Goals of Therapy in Wet Age-Related Macular DegenerationПодробнее

FSMA Fridays June 2018, Nutritional Labeling Requirements - Revisions and ChangesПодробнее

Incorporating Patient-Reported Outcomes in Drug LabelsПодробнее

Import Holds and Update on the FDA's PREDICT SystemПодробнее

AMD: Benefits of Screening and Early DiagnosisПодробнее

Labeling Requirements for Medical Devices in the USПодробнее

Age-Related Macular DegenerationПодробнее

Greg Conko on FDA Approval for AvastinПодробнее

An Animated Look at Age-Related Macular Degeneration and the Prior Authorization Payment ProcessПодробнее

Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMDПодробнее